Search

Abnormal expression of miR‐409‐3p has been found in several neurodevelopmental disorders, but whether it is dysregulated in the patients with acute cerebral infarction (ACI) has not been evaluated. The current study mainly focused on the clinical significance and the underlying mechanism of plasma miR‐409‐3p in the progression of ACI. The level of plasma miR‐409‐3p was determined in ACI patients (n = 80) and healthy controls (n = 30). Pearson correlation assay was performed to evaluate the association and cardiovascular risk factors. A receiver operating characteristic curve (ROC) was used to evaluate the diagnostic value of plasma miR‐409‐3p levels in patients with ACI. Dual luciferase reporter assay and western blot were performed to determine the possible target gene of miR‐409‐3p. Our data showed that the expression of plasma miR‐409‐3p in the ACI group was higher than that in the healthy controls. Furthermore, Pearson correlation analysis indicated a positive correlation between plasma miR‐409‐3p and the NIHSS score. ROC analysis indicated that plasma miR‐409‐3p could differentiate plasma miR‐409‐3p in ACI patients from healthy controls. Then, we explored the possible target genes of miR‐409‐3p. Interestingly, C1q and TNF‐related 3 (CTRP3), a novel adipose tissue‐derived secreted factor, was found to be a target gene of miR‐409‐3p. We found that knockdown of CTRP3 significantly induced PC12 cell apoptosis, even in PC12 cells transfected with miR‐409‐3p inhibitor. These data suggested that miR‐409‐3p induced PC12 cell apoptosis by targeting CTRP3. Altogether, elevated plasma miR‐409‐3p is correlated with disease severity and may be efficient for the early diagnosis of ACI. [ABSTRACT FROM AUTHOR]

Background: Uninterrupted use of oral anticoagulants before atrial fibrillation (AF) ablation can reduce the incidence of perioperative thromboembolic events. However, the effect of new oral anticoagulants on activated clotting time (ACT) in response to heparin during AF ablation in Chinese populations remains unknown. The aim of the present retrospective study was to investigate the value of ACTs in response to intraoperative heparin administration in patients using dabigatran or rivaroxaban., Methods: From January 2018 to December 2021, a total of 173 patients undergoing AF ablation were included in the study, in which 101 patients were treated with dabigatran, 72 patients were treated with rivaroxaban. The intraoperative ACT values were examined in both groups. The incidence of periprocedural complications was evaluated., Results: Initial heparin dosage (88 ± 19 U/kg vs. 78 ± 27 U/kg, P < 0.05), total heparin dosage (137 ± 41 U/kg vs. 106 ± 52 U/kg, P < 0.05) during the ablation procedure were higher in the dabigatran group than those in the rivaroxaban group. Mean ACT (280 ± 36 s vs. 265 ± 30 s, P < 0.05), and the percentage of ACTs within the therapeutic range (250-350 s) (74% ± 26% vs. 60% ± 29%, P < 0.05) were significantly lower in the dabigatran group than those in the rivaroxaban group, particularly in male patients. Furthermore, the average time of achieving the target ACT (250-350 s) was also found longer in the dabigatran group ( P < 0.05) as compared with the rivaroxaban group. No significant difference was found in the incidence of periprocedural complications between the two groups., Conclusions: The anticoagulant effect of uninterrupted rivaroxaban therapy appears to be more stable and efficient than dabigatran administration during catheter ablation in patients with AF., (© 2022 JGC All rights reserved; www.jgc301.com.)